Phase III results show ocriplasmin could be first pharmacological eye treatment for vitreomacular adhesion patients
15 August 2012 | By Novartis
Results of two Phase III studies...
List view / Grid view
15 August 2012 | By Novartis
Results of two Phase III studies...
15 August 2012 | By Bristol-Myers Squibb Company
Patient management programs for Sprycel® patients launched...
15 August 2012 | By GlaxoSmithKline
GSK has reached agreement to divest the majority of its “Classic Brands” in Australia...
14 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has grown again in the current financial year...
13 August 2012 | By Patheon
Patheon Inc. announced that Mark J. Kontny is no longer with the company...
13 August 2012 | By Sanofi
Breakthrough device design talks patients and caregivers through the injection process...
13 August 2012 | By Abbott
40 students living with CF each to receive a $2,500 CFCareForward Scholarship...
13 August 2012 | By Roche
First major treatment advance in more than 25 years for sight-threatening condition...
13 August 2012 | By AstraZeneca
NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval...
10 August 2012 | By Pfizer
Pfizer Inc. announced the Phase 3 INTORACT trial (B1771006) did not meet its primary endpoint...
10 August 2012 | By Roche
Phase III study met its co-primary endpoint...
9 August 2012 | By Phenomenex Inc
Phenomenex introduces two new Tabless Tube Holder accessories...
9 August 2012 | By AstraZeneca
AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals...
9 August 2012 | By Novo Nordisk
Sales grew 17% driven by Victoza®, NovoRapid® and Levemir®...
9 August 2012 | By Pfizer
Nodality, Inc.has announced a strategic collaboration with Pfizer Inc..